Akari Therapeutics plc ADR (0.01 USD) closed at $6.51 on Nov 12, down 12.62%, 96.6% below its 52-week closing high. Volume of 14.5K shares was 0.33× its 20-day average (below normal).
Split-adjusted performance: -10.6% over one month, +75.9% over six months, -72.5% over one year.
Short interest was 17.9K shares at the Oct 30 settlement, up 2.1% from the prior report (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 417 companies (100 = best)
Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AKTXAkari Therapeutics plc ADR (0.01 USD) | $6.51 | −12.62% | +75.9% | — | — | — | $14.9M | |
| QNRXQuoin Pharmaceuticals | $3.75 | −0.27% | −35.5% | — | — | — | $18.0M | Compare |
| CMMBChemomab Therapeutics Ltd. American Depositary Share | $1.40 | +3.70% | −17.6% | — | — | — | $11.3M | Compare |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | Compare |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | Compare |
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | Compare |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
